Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency
NCT03113760
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
15
Enrollment
INDUSTRY
Sponsor class
Conditions
NLRC4-MAS
XIAP Deficiency
Interventions
DRUG:
Tadekinig alfa
OTHER:
0.9% sodium chloride
Sponsor
AB2 Bio Ltd.